About 15 months after ending development of a different hereditary angioedema candidate due to liver safety worries, KalVista Pharmaceuticals, Inc. reported what analysts called best-case scenario results for its Phase III oral kallikrein inhibitor sebetralstat (KVD900) on 13 February. With the data in hand, KalVista said it plans to file sebetralstat for on-demand therapy in HAE by midyear, with expectations that it might become a foundational treatment for the rare swelling disorder.
KalVista Plans Quick FDA Filing After Phase III Success In On-Demand HAE Therapy
The firm’s oral kallikrein inhibitor might offer a better overall profile for on-demand treatment than currently approved therapeutic and prophylactic agents, analysts said.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.